| CF patients |
| n |
Total | 930 |
P. aeruginosa pos. | 292 |
P. aeruginosa MDR pos.a | 49 (=16.8% of P. aeruginosa pos.) |
| MDR P. aeruginosa, b |
| n | % |
Agec |
0–10 | 3 | 11 |
11–20 | 2 | 7 |
21–30 | 10 | 36 |
31–40 | 7 | 25 |
41–50 | 2 | 7 |
> 51 | 4 | 14 |
Resistance to d |
Colistin | 5 | 17 |
Fosfomycin | 20 | 69 |
Aztreonam | 29 | 100 |
Gentamicin | 27 | 93 |
Tobramycin | 18 | 62 |
Amikacin | 25 | 86 |
Carriage status e |
Intermittent | 1 | 4 |
Chronic | 27 | 96 |
- a defined as combined resistance to piperacillin/tazobactame, ceftazidime, imipenem, meropenem and ciprofloxacin
- b N = 29 isolates from N = 28 patients, i.e. one patient had two morphologically distinct isolates
- c median age 27.5 years (range 7 to 70 years); n = 28 patients
- d categorized as resistant (i.v. application) if MIC interpreted as intermediate or resistant
- e chronic: > 50% P. aeruginosa positive samples within 12 months; intermittent: < 50% P. aeruginosa positive samples within 12 months; negative: > 1 year P. aeruginosa negative